Genotyping of cutaneous melanoma.

ABSTRACT: Until recently, treatment options for patients with metastatic melanoma were very limited. This landscape has evolved dramatically since the discovery of activating mutations in the BRAF gene in ~45% of cutaneous melanomas. Vemurafenib, dabrafenib, and trametinib have all received regulatory approval for the treatment of metastatic melanoma patients with a BRAF^V600 mutation. Based on the necessity to document the presence of a BRAF^V600 mutation to prescribe these agents, molecular testing is now the standard of care in this disease. However, the options and rationale for testing are evolving rapidly due to an improved understanding of the molecular drivers and heterogeneity of melanoma. Such testing may identify rational combinatorial approaches t

SUBMITTER: Glitza IC 

PROVIDER: S-EPMC4306428 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature